Novartis Stock Tanks Following Third Major Pipeline Setback - Barron's

As reported by Barron's

Following two trial misses and a third clinical setback, analysts fear Novartis may miss its 2030 growth targets without further acquisitions.

▸ MARKET SAMACHAR VIEW

NEUTRAL

Read full article on Barron's ↗

Market Samachar is a news aggregator. This article was originally published by Barron's. Tap the button above to read the full story on their site.

INDIAN Can Karamtara Engineering IPO deliver long-term growth for high-risk investors? Markets-Economic Times
INDIAN Bessent dares traders to bet against Yen: ‘I am the house now’ Markets-Economic Times
INDIAN Global Market Today: Asian stocks to fall as oil stokes inflation fears Markets-Economic Times
INDIAN Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today —10 September 2026 mint - markets
INDIAN Apple Stock Update: Shares slide after iPhone 18 launch; what investors should know mint - markets
INDIAN Top stocks in focus today: Investors must watch Coal India, ICICI Bank, Wipro shares on Thu, 10 Sept | Triggers mint - markets
GLOBAL Iran likely to reverse-engineer captured US underwater drone - Reuters Reuters
GLOBAL ECB set to hike as Iran war fuels fresh inflation fears - Reuters Reuters

Novartis Stock Tanks Following Third Major Pipeline Setback - Barron's

More from Market Samachar